论文部分内容阅读
为进一步探讨Ki-67抗原评价非小细胞肺癌（NSCLC）的增殖活性和预后方面的价值，本文采用Ki-67多克隆抗体对85例有详细的临床、病理和随访资料的非小细胞肺癌进行了免疫组化研究。病人的平均年龄55．6±8．4岁；3年、5年总体生存率分别为66％和61％；中位随访时间为47个月；Ki-67平均标记率为30％±24％，此标记率明显高于其它研究者的研究结果；Ki-67标记率与病人的临床病理特征无关（P＞0．05）；Ki-67标记率＜3O％组病人的3年、5年生存率分别为80％、75％，≥30％组病人的3年、5年生存率分别为52％、49％，两组之间有显著性差别（X2=4．91，P=0．03）。以上结果提示：Ki-67多克隆抗体较单克隆抗体能更好地反映肿瘤的增殖活性，并可作为NSCLC的辅助预后指标。
To further investigate the value of Ki-67 antigen in evaluating the proliferative activity and prognosis of non-small cell lung cancer (NSCLC), we used Ki-67 polyclonal antibody to perform 85 cases of non-small cell lung cancer with detailed clinical, pathological and follow-up data. Immunohistochemical study. The average age of the patients was 55.6±8.4 years; the 3-year and 5-year overall survival rates were 66% and 61%, respectively; the median follow-up time was 47 months; the average labeling rate of Ki-67 was 30%±24%. The labeling rate was significantly higher than that of other investigators; the Ki-67 labeling rate was not associated with the patient’s clinicopathologic features (P>0.05); the Ki-67 labeling rate was <30% in patients with 3 years and 5 years. The survival rates were 80% and 75%, respectively. The 3-year and 5-year survival rates of patients in the ≥30% group were 52% and 49%, respectively. There was a significant difference between the two groups (X2=4.91, P=0. 03). The above results suggest that Ki-67 polyclonal antibody can better reflect the proliferation activity of tumor than monoclonal antibody, and can serve as an auxiliary prognostic indicator of NSCLC.